![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background. Sumatriptan has been used in the treatment of migraine and other vascular headaches since 1993 in the United States. Its side effects include chest pains in 3% to 8% of patients who have known cardiac risk factors. This is a case report of a 45‐year‐old woman with no history of cardiac risk factors who had a myocardial infarction after her monthly dose of oral sumatriptan. Methods. The patient was examined in the emergency room, evaluated by electrocardiography, and serial evaluations of cardiac enzymes over the next 24 h. She was admitted to the cardiology ward. A cardiac catherization and additional laboratory studies were performed the following day. Results. The catherization revealed normal heart function, but a 60% to 70% non‐flowing stenosis within the first septal perforator. Laboratory indices for cardiac risk were within normal ranges. Conclusions. Patients without cardiac risk factors may experience myocardial infarction following an oral dose of sumatriptan.